Drug intelligence / Profile preview

Meporan

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Topical

Overview

Meporan is a topical small molecule antiseptic developed by KrasPharma for the local treatment and prevention of wound infections. It is designed to reduce or eliminate pathogens at the wound site through broad-spectrum antimicrobial activity. As of the latest pipeline information, Meporan has completed preclinical development and the first stage of clinical trials (Phase 1) in Russia.

Brand names: Meporan

Targets

bc1 complex (Cytochrome bc1 complex (plasmodium))

Beyond the preview

Go deeper on Meporan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meporan.

Explore the full profile